Made in Britain Part Two: Pharmaceuticals

Why drugs giant GlaxoSmithKline is still breathing easily

Lucy Tobin reports from the £4bn-a-year production line in Hertfordshire that is bucking the trend for making drugs in the Far East

There's nothing very sexy about the large complex of buildings just off the high street in Ware, Hertfordshire. Green buzzers to open doors and a large "daily performance target" poster in the entrance hall give the appearance of a newly built school. The extreme security – locked doors, a photo ID to gain entry, and a decree to strip off all watches and jewellery before passing the threshold – is reminiscent of some kind of open prison. There are no whizzy bits of gadgetry, as the aeronautics giants dot about their sites, nor portraits of glamorous models showing off their wares, as you might see at a retailer's head office.

But these buildings are important. Without them, millions of asthma sufferers might struggle to breathe – and the UK's economy would be short of breath too. The Ware complex is one of the largest UK manufacturing sites for Britain's biggest pharmaceuticals company, GlaxoSmithKline. Across its 16 acres, 730 staff churn out billions of pounds worth of respiratory treatments each year: this is the birthplace of the drug Seretide (known in the US as Advair), GSK's top-selling medicine. Last year, Ware produced £4bn-worth of Seretide inhalers. About 95 per cent of them were exported to the likes of China, South Korea and the US.

The doomsayers who argue that Britain "just doesn't make stuff any more" should take a trip to Ware. This site has been turning out drugs since 1896, when the veteran pharma firm Allen & Hanbury (which Glaxo bought in the 1950s) first developed the land.

Today, however, it plays host to a very modern manufacturing story. Given the scale of its production – Ware produces 220,000 inhalers a day – the heavy doors leading to its assembly plant might be expected to reveal a cacophony of people. Instead, in a room the size of a football pitch there's no human noise, just silver tubes and mini conveyor belts on dozens of busy lorry-sized machines. Across four assembly lines, only six men (and they are all men: some parts of manufacturing are apparently unchanged) are at work.

Staff numbers here have been slashed by 50 per cent in the past two years, with more than 750 factory workers axed as part of what the company – and the corporate world more generally – euphemistically calls "efficiencies".

Depressing, yes, but culling staff numbers is one reason that GSK can still afford to make things in Britain. Big Pharma's UK manufacturing isn't entirely healthy. Last year Pfizer closed its only research and development facility in the UK, a factory in Sandwich, Kent which developed the impotence drug Viagra. Other drug makers are also shifting their focus from tired Western economies to fast-growing emerging markets: Glaxo's domestic rival AstraZeneca last year announced that it had chosen China to home the most expensive factory it had ever developed, spending $200m (£128m) on a huge plant in Jiangsu province. At the same time, Astra last year closed down its research facility in Loughborough which employed almost 1,200 Britons.

But GSK is staying put. Indeed, in March it confirmed plans to invest £350m in its first new British manufacturing site – in Cumbria – in almost four decades.

"To move a plant would be an enormous investment decision when we can comfortably satisfy demand – not just for the UK but for the whole world – from Ware," says Jo Barrett, GSK's respiratory product stream director at Ware. "It would involve massive technology costs plus huge training, whilst here we have easy access to Europe and good logistics to overseas markets." She adds that having an R&D site just across the road in another part of GSK's complex has benefits too, including on-site scientists helping set up manufacturing lines. They created Relovair, the new respiratory medicine which GSK hopes will be another blockbuster and which is set to go to the regulators later this year, and are now liaising with the factory about gearing up for production.

Ms Barrett adds: "In pharma, it's not just about finding the cheapest method of production. Regulation is strict and plants in some local markets would not meet the requirements. In the past few months we've had the FDA [the US regulator], Saudi Arabian and Turkish regulators checking out our factory, plus the UK regulators are often on site. Overseas production may not be able to meet the standards that we can here."

The second reason helping GSK to continue making asthma drugs in Britain is a lack of immediate competition concerns. Tablets and capsules are easily replicable once their patents run out. Seretide's patent has already expired in several countries, but the complexities of making both the powder and the "diskus" inhaler device have so far deterred generic manufacturers from taking a slice out of the drug's £5bn-a-year sales. The same is true of oncology medicines: they sell in small volumes and there would be little cost savings in moving overseas.

Last year, the sector's exports hit £22.5bn, up £300m from 2010 and helping pharmaceuticals maintain their position as having the largest trade balance of any UK industry at £6.1bn in 2011. The Government is certainly aware of that: the Budget confirmed the introduction of a "patent box" with a lower rate of corporation tax on profits generated from UK-owned intellectual property. Glaxo – whose chief executive, Sir Andrew Witty, has been a member of David Cameron's business advisory group since 2010 – said that was a major factor in its decision to build and maintain its UK manufacturing.

But Big Pharma knows just how critical it is to the UK economy – and will become increasingly vocal about that fact in the coming months. That's because this autumn, the drugs industry will enter its next round of pricing negotiations with the Government. Under the Pharmaceutical Price Regulation Scheme, medicine rates are renegotiated every five years, with a limit on profits that companies can earn from supplying drugs to the NHS. Earlier this month, Stephen Whitehead, the chief executive of the Association of the British Pharmaceutical Industry, said Britain must "recognise and reward the investment that goes into creating innovative new medicines". Otherwise, "our manufacturers will go abroad", he warned. "Our industry, our economy, and our healthcare system will suffer."

Global recipe, local production

A package of Seretide requires chemical compounds brought in from Scotland and Singapore, lactose (which carries the drug particles to the patient's lungs) from the Netherlands and New Zealand, plastic inhaler parts made in Kings Lynn, and foil strips from Germany.

These are bought together across three vast rooms, entirely by machine. The first production line sees medicine particles mixed together before mechanised pincers drop them into wells in the foil strips.

In the assembly room, a single worker supervises as another immense machine creates reels of foil doses, broken up into the exact number of doses per inhaler. A roller then winds each of these into a spiral, which a mechanical hand inserts into one half of the "diskus" device. The other half is then stamped and sealed on top.

Lasers etch on details of the dosage strength and batch number, and testing machines automatically swipe any mistakes into a bin.

The fastest of GSK's machines produces 7,500 inhalers an hour. A lone man, labouring under a huge US-style sign bearing the slogan "welcome to the home of the world's best respiratory device" then prepares products for the packing room.

Here machines foil-wrap inhalers for warmer climes such as the Middle East, and they are boxed ready for the pharmacy shelf. Cartons are packed on to pallets, ready to be moved around the UK, sent (by road) to Antwerp and on to the rest of Europe, or shipped to the US and further afield.

A model of a Neanderthal man on display at the National Museum of Prehistory in Dordogne, France
Richard Dawkins dedicated his book 'The Greatest Show on Earth' to Josh Timonen
newsThat's Richard Dawkins on babies with Down Syndrome
Arts and Entertainment
Eye of the beholder? 'Concrete lasagne' Preston bus station
architectureWhich monstrosities should be nominated for the Dead Prize?
ebooksAn evocation of the conflict through the eyes of those who lived through it
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

AIFMD Business Analyst / Consultant - Investment Management

£450 - £600 per day: Harrington Starr: AIFMD Business Analyst / Consultant - I...

Business Analyst Solvency II SME (Pillar 1, 2 & 3) Insurance

£450 - £600 per day: Harrington Starr: Business Analyst Solvency II SME (Pilla...

Manager - SAS - Data Warehouse - Banking

£350 - £365 per day: Orgtel: Manager, SAS, Data Warehouse, Banking, Bristol - ...

SQL DBA/Developer

£500 per day: Harrington Starr: SQL DBA/Developer
 SQL, C#, VBA, Linux, SQL Se...

Day In a Page

Middle East crisis: We know all too much about the cruelty of Isis – but all too little about who they are

We know all too much about the cruelty of Isis – but all too little about who they are

Now Obama has seen the next US reporter to be threatened with beheading, will he blink, asks Robert Fisk
Neanderthals lived alongside humans for centuries, latest study shows

Final resting place of our Neanderthal neighbours revealed

Bones dated to 40,000 years ago show species may have died out in Belgium species co-existed
Scottish independence: The new Scots who hold fate of the UK in their hands

The new Scots who hold fate of the UK in their hands

Scotland’s immigrants are as passionate about the future of their adopted nation as anyone else
Britain's ugliest buildings: Which monstrosities should be nominated for the Dead Prize?

Blight club: Britain's ugliest buildings

Following the architect Cameron Sinclair's introduction of the Dead Prize, an award for ugly buildings, John Rentoul reflects on some of the biggest blots on the UK landscape
Culture Minister Ed Vaizey: ‘lack of ethnic minority and black faces on TV is weird’

'Lack of ethnic minority and black faces on TV is weird'

Culture Minister Ed Vaizey calls for immediate action to address the problem
Josephine Dickinson: 'A cochlear implant helped me to discover a new world of sound'

Josephine Dickinson: 'How I discovered a new world of sound'

After going deaf as a child, musician and poet Josephine Dickinson made do with a hearing aid for five decades. Then she had a cochlear implant - and everything changed
Greggs Google fail: Was the bakery's response to its logo mishap a stroke of marketing genius?

Greggs gives lesson in crisis management

After a mishap with their logo, high street staple Greggs went viral this week. But, as Simon Usborne discovers, their social media response was anything but half baked
7 best quadcopters and drones

Flying fun: 7 best quadcopters and drones

From state of the art devices with stabilised cameras to mini gadgets that can soar around the home, we take some flying objects for a spin
Andy Murray: I quit while I’m ahead too often

Andy Murray: I quit while I’m ahead too often

British No 1 knows his consistency as well as his fitness needs working on as he prepares for the US Open after a ‘very, very up and down’ year
Ferguson: In the heartlands of America, a descent into madness

A descent into madness in America's heartlands

David Usborne arrived in Ferguson, Missouri to be greeted by a scene more redolent of Gaza and Afghanistan
BBC’s filming of raid at Sir Cliff’s home ‘may be result of corruption’

BBC faces corruption allegation over its Sir Cliff police raid coverage

Reporter’s relationship with police under scrutiny as DG is summoned by MPs to explain extensive live broadcast of swoop on singer’s home
Lauded therapist Harley Mille still in limbo as battle to stay in Britain drags on

Lauded therapist still in limbo as battle to stay in Britain drags on

Australian Harley Miller is as frustrated by court delays as she is with the idiosyncrasies of immigration law
Lewis Fry Richardson's weather forecasts changed the world. But could his predictions of war do the same?

Lewis Fry Richardson's weather forecasts changed the world...

But could his predictions of war do the same?
Kate Bush asks fans not to take photos at her London gigs: 'I want to have contact with the audience, not iPhones'

'I want to have contact with the audience, not iPhones'

Kate Bush asks fans not to take photos at her London gigs
Under-35s have rated gardening in their top five favourite leisure activities, but why?

Young at hort

Under-35s have rated gardening in their top five favourite leisure activities. But why are so many people are swapping sweaty clubs for leafy shrubs?